What Makes Elevance Health (ELV) an Investment Choice?

Harding Loevner, an asset management company, released its “Global Equity Strategy” third-quarter 2025 investor letter.  A copy of the letter can be downloaded here. The fund returned 2.62% gross (2.52% net) in the third quarter of 2025, compared to a 7.74% return for the MSCI All Country World Index and 7.36% gain for the MSCI World Index. YTD, the strategy rose 10.61% (net) compared to 18.86% and 17.83% for the indexes. The firm highlighted in the letter that the last six months represented one of the strongest momentum phases in over 70 years. Since the beginning of the year, high-momentum stocks have outperformed low-momentum stocks by a remarkable 45 percentage points, with much of the growth driven by advancements in AI. In addition, please check the fund’s top five holdings to know its best picks in 2025.

In its third-quarter 2025 investor letter, Harding Loevner Global Equity Strategy highlighted stocks such as Elevance Health, Inc. (NYSE:ELV). Elevance Health, Inc. (NYSE:ELV) is a health benefits company. The one-month return of Elevance Health, Inc. (NYSE:ELV) was 5.19%, and its shares lost 15.84% of their value over the last 52 weeks.  On December 03, 2025, Elevance Health, Inc. (NYSE:ELV) stock closed at $330.75 per share, with a market capitalization of $74.478 billion.

Harding Loevner Global Equity Strategy  stated the following regarding Elevance Health, Inc. (NYSE:ELV) in its third quarter 2025 investor letter:

“Health Care is the portfolio’s fourth-largest sector holding and one of its largest overweights. Our 11 Health Care companies span pharmaceuticals, biotechnology, life sciences, and equipment and services. We also added a new US holding this quarter, Elevance Health, Inc. (NYSE:ELV), a major medical-care organization. Readers may remember that we exited industry leader UnitedHealthcare in May amid a criminal investigation into its Medicare Advantage business. Like UnitedHealthcare, Elevance enjoys a favorable industry structure-with an entrenched position in consolidated, regulated markets but at a much more palatable valuation and with less legal risk.”

Elevance Health (ELV) Drops 18.66% After Dismal Q2 Earnings

Elevance Health, Inc. (NYSE:ELV) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 82 hedge fund portfolios held Elevance Health, Inc. (NYSE:ELV) at the end of the third quarter, which was 67 in the previous quarter. In Q3 2025, Elevance Health, Inc. (NYSE:ELV) reported $50.1 billion of operating revenue, an increase of 12% year-over-year. While we acknowledge the risk and potential of Elevance Health, Inc. (NYSE:ELV) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Elevance Health, Inc. (NYSE:ELV) and that has 10,000% upside potential, check out our report about this cheapest AI stock.

In another article, we covered Elevance Health, Inc. (NYSE:ELV) and shared Madison Large Cap Fund’s views on the company. In addition, please check out our hedge fund investor letters Q3 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.